• Christopher R. Cline, chief financial officer, reported acquisition of 4,250 shares of common stock on May 4, 2026 via vesting of performance-based restricted stock units.
• Disposed of 2,181 shares on May 5 at USD 46.65, described as a sell-to-cover transaction tied to tax withholding.
• Sold 310 shares on May 6 at USD 43.95 under a Rule 10b5-1 plan.
• Beneficial ownership stood at 118,658 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001943192-26-000004), on May 06, 2026, and is solely responsible for the information contained therein.